The likes of Pfizer and Lilly have announced the halting of research in light of Moscow’s offensive against Ukraine
© Getty Images / Monty Rakusen
Several major international pharmaceutical companies including Pfizer, Lilly and Sanofi have issued statements, announcing the suspension of new clinical trials in Russia in light of its military campaign against Ukraine.
On Monday, Pfizer Inc. took a stand on Moscow’s offensive, denouncing the “brutal situation it has created.” The US pharma giant said that it would “no longer initiate new clinical trials in Russia.” Additionally, the company will “stop recruiting new patients in our ongoing clinical trials in the country,” with such research being transitioned to “alternative sites outside Russia.” However, Pfizer stressed that it was committed to “providing needed medicines to the patients already enrolled in clinical trials” in the country.
Other measures taken by the pharma giant in response to the war in Ukraine include the cessation of all planned investments in Russia as well as the earmarking of all profits of Pfizer’s Russian subsidiary to be donated to the people of Ukraine.
The company will, however, continue supplying essential medicines to Russia in line with its “foundational principle of putting patients first.”